Your browser doesn't support javascript.
loading
Clinical efficacy of weight loss herbal intervention therapy and lifestyle modifications on obesity and its association with distinct gut microbiome: A randomized double-blind phase 2 study.
Cao, Ming-Zhuo; Wei, Chun-Hua; Wen, Ming-Chun; Song, Ying; Srivastava, Kamal; Yang, Nan; Shi, Yan-Mei; Miao, Mingsan; Chung, Danna; Li, Xiu-Min.
Afiliação
  • Cao MZ; Academy of Chinese Medical Sciences, Henan University of Chinese Medicine, Zhengzhou, China.
  • Wei CH; Department of Medicine, Wei-en Hospital, Weifang, China.
  • Wen MC; Department of Medicine, Wei-en Hospital, Weifang, China.
  • Song Y; Department of Pathology, Microbiology & Immunology, New York Medical College, Valhalla, NY, United States.
  • Srivastava K; Department of Pathology, Microbiology & Immunology, New York Medical College, Valhalla, NY, United States.
  • Yang N; General Nutraceutical Technology, LLC, Elmsford, NY, United States.
  • Shi YM; Department of Pathology, Microbiology & Immunology, New York Medical College, Valhalla, NY, United States.
  • Miao M; General Nutraceutical Technology, LLC, Elmsford, NY, United States.
  • Chung D; Academy of Chinese Medical Sciences, Henan University of Chinese Medicine, Zhengzhou, China.
  • Li XM; Academy of Chinese Medical Sciences, Henan University of Chinese Medicine, Zhengzhou, China.
Front Endocrinol (Lausanne) ; 14: 1054674, 2023.
Article em En | MEDLINE | ID: mdl-37033234
ABSTRACT
Goals To assess the efficacy and safety of Chinese Medicine Prescription "W-LHIT" in subjects with simple obesity, and to explore its potential mechanism of action.

Methods:

Thirty-seven patients aged 18 to 60 from Wei-En hospital (Weifang City, Shandong, China), participated in a double blinded, placebo-controlled study. Subjects were randomly divided into 2 groups, 18 in treatment and 19 in placebo group. The treatment group took the "W-LHIT" capsules for two months, while the control group received placebo capsules. Both groups accepted healthy lifestyle education materials. After a 2-month treatment, the placebo group transferred to open-label treatment after unblinding.

Results:

72.22% participants in the treatment group lost more than 5% of their body weight, compared with 36.84% in the placebo group (p < 0.001). Body weight loss and body mass index reduction of the treatment group were also significantly higher than those of the placebo group (p < 0.05). These changes were accompanied by increased abundance of Akkermansia muciniphila and Enterococcus faecium, and decreased abundance of Proteobacteria in gut microbiota. Furthermore, the treatment group also showed improvement in obesity-related comorbidities such as hypertension and elevation of liver enzymes. No serious adverse reactions were found during the study period. Weight did not rebound at a follow-up visit 2 months after treatment.

Conclusion:

W-LHIT significantly improved body weight and comorbid conditions without obvious adverse reaction or rebound weight gain. These effects were associated with increased abundance of probiotics in gut microbiota. W-LHIT may have a potential for treating obesity in conjunction with healthy lifestyle modifications.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Microbioma Gastrointestinal Tipo de estudo: Clinical_trials / Risk_factors_studies Limite: Humans Idioma: En Ano de publicação: 2023 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Microbioma Gastrointestinal Tipo de estudo: Clinical_trials / Risk_factors_studies Limite: Humans Idioma: En Ano de publicação: 2023 Tipo de documento: Article